Coagulation and fibrinolytic parameters in patients with pulmonary hypertension

Clinical Cardiology

Volumn 19, Issue 7, 1996, Pages 549-554

  Altman, Raul ^a   Scazziota, Alejandra ^a   Rouvier, Jorge ^a   Gurfinkel, Enrique ^a   Favaloro, Roberto ^b   Perrone, Sergio ^b   Fareed, Jawed ^c  

^a Ctro Estud Medicos y Bioquimicos   (Argentina)

^b HOSPITAL UNIVERSITARIO FUNDACIÓN FAVALORO   (Argentina)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

fibrinolysis; pulmonary hypertension; tissue factor pathway inhibitor; venous occlusion test

Indexed keywords

ANTICOAGULANT PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EUGLOBULIN LYSIS TEST; FEMALE; FIBRINOLYSIS; HEART RIGHT ATRIUM PRESSURE; HUMAN; LUNG ARTERY PRESSURE; MALE; PULMONARY HYPERTENSION; VASCULAR ENDOTHELIUM;

EID: 0029790112     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960190706     Document Type: Article

References (28)

1. Loscalzo J: Endothelial dysfunction in pulmonary hypertension (Edit). N Engl J Med 1992;327:117-119
2. Badesch DB, Wynne KM, Bonvallet S, Voelkel NF, Ridgway Ch, Groves BM: Hypothyroidism and primary pulmonary hypertension: An autoimmune pathogenetic link? Ann Intern Med 1993; 119:44-46
3. Rostagno C, Gensini GF, Neri Serneri GG: Thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992;327:1457-1458
4. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, Loyd JE: An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992;327:70-75
5. 2 and prostacyclin biosynthesis in children and adolescents with pulmonary vascular disease. Circulation 1993;88(part 1):2117-2122
6. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid W, Stewart DJ: Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328:1732-1739
7. Yoshibayash M, Nishioka K, Nakao K, Saito Y, Matsumura M, Ueda T, Temma S, Shirakami G, Imura H, Mikawa H: Plasma endothelin concentration in patients with pulmonary hypertension associated with congenital heart defects. Circulation 1991;84:2280-2285
8. Eisenberg PR, Lucore C, Kaufman L, Sobel BE, Jaffe AS, Rich S: Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension. Circulation 1990;82:841-847
9. Rabinovitch M, Andreu M, Thom H, Trusler GA, Williams WG, Rowe RD, Olley PM: Abnormal endothelial factor VIII associated with pulmonary hypertension and congenital heart defects. Circulation 1987;75:1043-1052
10. Keber I, Keber D, Stegnar M, Vene N: Tissue plasminogen activator release in chronic venous hypertension due to heart failure. Thromb Haemostas 1992;68:321-324
11. Buckell M: The effect of citrate on euglobulin methods of estimating fibrinolytic activity. J Clin Path 1958;11:403-405
12. Laurell CB: Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Ann Biochem 1966;15:45-52
13. Keber D: On the use of different correction factors for haemoconcentration (letter). Thromb Haemostas 1983;49:245
14. Wieczorek I, Ludlam CA, MacGregor I: Venous occlusion does not release von Willebrand factor, factor VIII or PAI-1 from endothelial cells. The importance of consensus on the use of correction factors for haemoconcentration. Thromb Haemostas 1993;69:91-93
15. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL: Primary pulmonary hypertension: Natural history and the importance of thrombosis. Circulation 1984;70:580-597
16. Weissman NJ, Fuster V: Diagnosis of pulmonary artery hypertension. Heart Dis Stroke 1992;1:196-201
17. Roberts JD, Lang P, Bigatello LM, Vlahakes GJ, Zapol WM: Inhaled nitric oxide in congenital heart disease. Circulation 1993; 87:447-453
18. 2 and prostacyclin biosynthesis in children and adolescents with pulmonary vascular disease. Circulation 1993;88(part 1):2117-2122
19. Wessel DL, Adatia I, Giglia TM, Thompson JE, Kulik TJ: Use of inhaled nitric oxide and acetylcholine in the evaluation of pulmonary hypertension and endothelial function after cardiopulmonary bypass. Circulation 1993;88(part1):2128-2138
20. Rich S, Kaufmann E, Levy PS: The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76-81
21. Boyer-Neumann C, Brenot F, Wolf M, Peynaud-Debayle E, Duroux P, Meyer D, Anglés-Cano E, Simonneau G: Continuous infusion of prostacyclin decreases plasma levels of t-PA and PAI-1 in primary pulmonary hypertension. Thromb Haemost 1995;73: 735-736
22. Schulman LL, Grossman BA, Owen J: Platelet activation and fibrinopeptide formation in pulmonary hypertension. Chest 1993;104: 1690-1693
23. Komuro I, Kurihara H, Sugiyama T, Yoshizumi M, Takaku F, Yazaki Y: Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells. FEBS Lett 1988;238: 249-252
24. Dubin D, Pratt RE, Kooke JP, Dzau VJ: Endothelin, a potent vasoconstrictor, is a vascular smooth muscle mitogen. J Vasc Biol Med 1989;1:150-154
25. Fuchs J, Mlczoch J, Niessner H: Abnormal fibrinolysis in primary pulmonary hypertension (abstr). Eur Heart J 1981;2:A168
26. Urano T, Sumiyoshi K, Pietraszek MH, Takada Y, Takada A: PAI-1 plays an important role in the expression of t-PA activity in the euglobulin clot lysis by controlling the concentration of free t-PA. Thromb Haemostas 1991;66:474-478
27. D'Alonzo GE, Barst RJ: Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT, Levy PS, Pietra GG, Reid LM, Reeves JT, Rich S, Vreim CE, Williams GW, Wu M. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343-349
28. Rapaport SI: The extrinsic pathway inhibitor: A regulator of tissue factor-dependent blood coagulation. Thromb Haemostas 1991;66: 6-15